We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$9.59B
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$2.79B
AUM Growth
-$56M
(-2%)
Cap. Flow
-$584M
Cap. Flow
% of AUM
-20.93%
Top 10 Holdings %
Top 10 Hldgs %
31.86%
Holding
129
New
19
Increased
19
Reduced
27
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$67.9M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
+$33.9M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$32.9M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$32.8M |
| 5 |
Acadia Healthcare
ACHC
|
+$27.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$130M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$80M |
| 3 |
AET
Aetna Inc
AET
|
+$42M |
| 4 |
CVS Health
CVS
|
+$39.3M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
+$31.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.55% |
| 2 | Miscellaneous | 19.21% |
| 3 | Financials | 1.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $129M | 4.64% |
6,609,894
| – | – |
|
2
Q32 Bio
QTTB
$381M
| $119M | 4.28% |
290,391
| – | – |
|
|
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
| $94.8M | 3.4% |
1,540,448
+1,056,393
| +218% | +$67.9M |
|
4
Viatris
VTRS
$19.5B
| $67.4M | 2.42% |
1,842,111
+100,000
| +6% | +$3.75M |
|
|
PTLA
5
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $65.4M | 2.34% |
2,455,586
+1,008,953
| +70% | +$32.9M |
|
|
DBVT
6
DBV Technologies
DBVT
$861M
| $65.1M | 2.33% |
290,000
| – | – |
|
7
AnaptysBio
ANAB
$1.7B
| $64.6M | 2.31% |
647,466
+84,477
| +15% | +$7.01M |
|
|
XLRN
8
DELISTED
Acceleron Pharma
XLRN
| $64M | 2.29% |
1,117,651
-9,149
| -0.8% | -$450K |
|
|
ECYT
9
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $62.4M | 2.24% |
3,514,084
+1,189,785
| +51% | +$20.4M |
|
|
XENT
10
DELISTED
Intersect ENT, Inc
XENT
| $61.8M | 2.21% |
2,147,950
+1,127,950
| +111% | +$33.9M |
|
|
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $59.8M | 2.14% |
917,000
-242,000
| -21% | -$14.2M |
|
12
BioCryst Pharmaceuticals
BCRX
$2.58B
| $52.7M | 1.89% |
6,910,789
+847,293
| +14% | +$5.69M |
|
|
13
Acadia Healthcare
ACHC
$2.64B
| $50.1M | 1.8% |
1,424,571
+683,555
| +92% | +$27.2M |
|
14
argenx
ARGX
$65.9B
| $49.8M | 1.78% |
656,500
+209,471
| +47% | +$18.6M |
|
15
Sarepta Therapeutics
SRPT
$2.43B
| $47.8M | 1.71% |
296,000
| – | – |
|
16
Brookdale Senior Living
BKD
$2.85B
| $46.3M | 1.66% |
4,707,912
+2,402,139
| +104% | +$22.1M |
|
17
Aclaris Therapeutics
ACRS
$876M
| $44.9M | 1.61% |
3,093,416
+347,711
| +13% | +$5.96M |
|
|
18
CALL
CVS Health
CVS
$124B
| $44.6M | 1.6% |
566,800
| – | – |
|
19
Xeris Biopharma Holdings
XERS
$1.57B
| $43.9M | 1.57% |
2,498,666
| – | – |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $41M | 1.47% |
525,000
+50,050
| +11% | +$3.48M |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $39.6M | 1.42% |
840,911
-459,454
| -35% | -$25.6M |
|
22
Glaukos
GKOS
$10.6B
| $37M | 1.32% |
569,356
-184,866
| -25% | -$9.07M |
|
23
Editas Medicine
EDIT
$473M
| $36.9M | 1.32% |
1,158,841
| – | – |
|
24
Centene
CNC
$33.6B
| $35.5M | 1.27% |
490,000
-159,072
| -25% | -$11M |
|
25
eHealth
EHTH
$30.4M
| $34.7M | 1.24% |
1,227,061
+122,109
| +11% | +$3.24M |
|
Similar funds
OAM
BTI
WAM
MSE
VF
GGHC
A
Deerfield Management's Q3 2018 Portfolio in Review
As of Q3 2018, Deerfield Management held 129 positions worth $2.79B, down 2% from $2.85B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Deerfield Management withdrew a net $584M in Q3 2018, closing 26 positions and reducing 27 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $130M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $29.9M.
- Deerfield Management's largest Q3 2018 buy was NEVRO CORP.: 525,040 shares worth $29.9M.
- Deerfield Management added most to Aerie Pharmaceuticals in Q3 2018, an estimated $67.9M increase.
- Deerfield Management's biggest Q3 2018 reduction was Tandem Diabetes Care, cutting an estimated $80M.
- Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2018, selling an estimated $130M.
- Deerfield Management's ten largest holdings make up 32% of its $2.79B portfolio in Q3 2018.
- Deerfield Management opened 19 new positions and closed 26 in Q3 2018.
- Deerfield Management's portfolio value fell 2% quarter-over-quarter to $2.79B.
Based on Deerfield Management's 13F filing for Q3 2018, filed 14 Nov 2018.